Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT05551949 Enrolling by invitation - Clinical trials for Urinary Tract Infections

Preventing Recurrent UTI With Vaginal Estrogen

PRUVE
Start date: January 31, 2023
Phase: Phase 4
Study type: Interventional

Among postmenopausal women who suffer from recurrent urinary tract infections (UTI), vaginal estrogen therapy prevents UTI recurrences for 50% of sufferers. This research will investigate why some women benefit but others do not, focusing on (a) the effects of vaginal estrogen therapy on the bacteria that inhabit the vagina and bladder, (b) its influence on immune responses in both compartments, and (c) the extent to which those changes are critical to successful UTI prevention. The findings will be a first step in the development of more effective strategies to prevent UTI, one of the most common and costly benign urologic conditions.

NCT ID: NCT04881487 Enrolling by invitation - Clinical trials for Recurrent Pancreatic Ductal Adenocarcinoma

Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy

ARCADE
Start date: July 5, 2021
Phase: N/A
Study type: Interventional

A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of additional local ablative therapy compared to current standard of care alone, on survival after recurrence in patients with isolated local pancreatic ductal adenocarcinoma (PDAC) recurrence. The most important secondary endpoint is quality of life. Other secondary endpoints are treatment response, acute and late toxicity, overall survival, progression-free survival, local progression-free survival, distant metastases free survival and reasons for non-eligibility or exclusion.

NCT ID: NCT04077580 Enrolling by invitation - Clinical trials for Recurrent Urinary Tract Infection

The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI

ImpresUWP3
Start date: November 1, 2019
Phase: Phase 4
Study type: Interventional

Recurrent urinary tract infection (UTI) in elderly women is a major driver of antibiotic prescription. Hence, the question of feasible and appropriate preventive measures are important issues in this field. Methenamine hippurate is frequently prescribed in Norway and Sweden as prophylaxis for recurrent UTI. Methenamine hippurate acts via the production of formaldehyde from hexamine, which in turn acts as a bacteriostatic agent, therefore methenamine hippurate is not defined as an antibiotic. According to a Cochrane review 2012 the rates of adverse events for preventing UTI was low. Although this review showed methenamine hippurate might be effective in preventing UTI in the short term, there is a need for large well-conducted randomised controlled trial (RCT) to clarify both the safety and effectivity of preventive methenamine hippurate for longer term use. This is particularly important for longer term use for people without neuropathic bladder disorders. A Norwegian longitudinal observational study including women aged 50-80 years with recurrent UTI indicated a significant and large reduction of more than 50% in antibiotic prescriptions for UTI after start of prophylactic methenamine hippurate. This further strengthens the need for an RCT of methenamine hippurate as prophylaxis for recurrent UTI.

NCT ID: NCT03721133 Enrolling by invitation - Clinical trials for Lung Cancer Recurrent

Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients

Start date: December 4, 2018
Phase:
Study type: Observational

From literature review, circulating tumor cell was demonstrated its possible role in disease relapse. It was rare nit could be identified in all lung cancer patients. In addition, circulating tumor cell usual aggregate to form circulating tumor micro-emboli and caused distant metastases. Therefore, circulating tumor cell could play a role in detect disease relapse and appropriate treatment could be given more earlier and further prolong patients' survival. However, the detail clinical significance of circulating tumor still remains unknown. The aim of this study was evaluate the clinical significance, including present timing, numbers, and correlation to disease relapse, of circulating tumor cell in lung cancer patients. The investigators want to clarify the clinical significance between circulating tumor cell and clinical presentation of lung cancer in order to establish new prediction model and improve lung cancer patients' survival.

NCT ID: NCT03552211 Enrolling by invitation - Clinical trials for Progressive Multiple Sclerosis

Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis

IPBio-SeP
Start date: May 30, 2018
Phase:
Study type: Observational

Background: High dose biotin is a therapeutic option for French progressive Multiple Sclerosis (MS) patients, without relapse for at least one year, since June 1, 2016. Despite the inflammatory activity of progressive forms of MS is known to be low, several publications mentioned clinical and/or radiological activity for biotin-treated patients. Objectives: 1. To determine if high dose biotin increase the clinical inflammatory activity of patients with a progressive form of MS. 2. To compare the clinical characteristics of the relapses that occurred with biotin or not. 3. To describe the characteristics of the patients with a clinical inflammatory activity with biotin. Methods: This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat. The main judgment criterion is the annualized relapse rate (ARR) from the beginning of the biotin to the last evaluation available before the data extraction. A Student's t test will be used. A negative binomial modelling with relapses counting over a period of exposure and taking into account the inter and intra center variability will be used. The statistical tests will be adapted to the nature of the variables concerning the secondary judgment criteria. Expected results: This French national study will provide a better knowledge of the inflammatory activity of the progressive forms of MS treated with high dose biotin. If an increased clinical inflammatory activity is highlighted with biotin a prospective study will be necessary to confirm the result before a specific information of the scientific community and the patients about this risk or even an amendment of prescription rules in order to secure the use of the product. On the contrary, the absence of increased risk of clinical inflammatory activity with biotin would help to reassure the prescriber and the patient about the innocuity of the treatment.

NCT ID: NCT03349528 Enrolling by invitation - Bipolar Depression Clinical Trials

Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression

Start date: December 11, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if taking a probiotic supplement versus a placebo will reduce relapse and improve the clinical course among participants who have been hospitalized for bipolar depression.

NCT ID: NCT03025932 Enrolling by invitation - Hiatal Hernia Large Clinical Trials

Recurrence Rate After Laparoscopic Repair of Large Hiatal Hernia

Start date: January 2016
Phase:
Study type: Observational

Patients who underwent laparoscopic repair of large hiatal hernias and anterior fundoplication with mesh are examined for their recurrence rate one year after surgery.

NCT ID: NCT02958839 Enrolling by invitation - Atrial Fibrillation Clinical Trials

Relationship Between Fibroblast Growth Factor 23 and Recurrence of Atrial Fibrillation After Catheter Ablation

REBECCA
Start date: November 2016
Phase: N/A
Study type: Observational

To investigate whether fibroblast growth factor 23 can be used to predict recurrence after catheter ablation for atrial fibrillation and to provide an objective basis for the clinical selection of the optimal patients for catheter ablation.

NCT ID: NCT02742493 Enrolling by invitation - Gingival Recession Clinical Trials

RCT for the Effectiveness of 3 Orthodontic Retention Schemes on Post-treatment Stability and Gingival Recession

OrthRe10tion
Start date: April 2016
Phase: N/A
Study type: Interventional

The present study aims to assess the effectiveness of three different retention schemes used to maintain tooth position after orthodontic treatment with fixed orthodontic appliances (stability) and to evaluate possible association between retention scheme and gingival recessions on the lingual surfaces of the lower anterior teeth seen for up to 5 years post-treatment. Moreover the possible association between primary relapse tendency and long term occlusal stability will be evaluated.

NCT ID: NCT02097394 Enrolling by invitation - Colon Polyps Clinical Trials

The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps

Start date: June 2013
Phase: Phase 4
Study type: Interventional

The study hypothesis is whether digestion enzyme(Combizym) and intestinal flora drugs(Bifidobacteria) can decease recurrence rate of colon polyps